GlassScriptPhysician profile
Benjamin R Nadeau
NPI 1457563728
$3,108.82
in general payments reported to CMS, 2019-2025
45 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $130 · 2021: $11.92 · 2022: $33.88 · 2023: $438 · 2024: $245 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.83 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $326.39 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $312.07 | 2020-2025 | Imfinzi, Tagrisso, Calquence |
| Astellas Pharma US INC | $217.55 | 2019-2025 | Vyloy, Padcev |
| Novartis Pharmaceuticals Corporation | $153.86 | 2019-2025 | |
| Pfizer INC. | $143.06 | 2019-2025 | |
| Janssen Biotech, INC. | $138.08 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Mirati Therapeutics, INC. | $133.65 | 2023 | Krazati |
| Aveo Pharmaceuticals, INC. | $130.87 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $112.11 | 2019-2025 | Libtayo |
| Exelixis INC. | $110.42 | 2023-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $106.60 | 2019-2025 | Keytruda |
| Gilead Sciences, INC. | $96.80 | 2021-2025 | Trodelvy |
| Abbvie INC. | $86.87 | 2019-2025 | |
| Daiichi Sankyo INC. | $84.83 | 2024-2025 | Enhertu, Datroway |
| Taiho Oncology, INC. | $72.75 | 2025 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Nadeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.